Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19

Some effective drugs have been approved or issued an Emergency Use Authorization for the treatment of COVID-19 in hospitalized patients, but post-market surveillance is warranted to monitor adverse events. We reviewed clinical trials and case reports in patients with moderate-to-severe COVID-19 infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Jen-Yu, Mao, Yan-Chiao, Liu, Po-Yu, Lai, Kuo-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536968/
https://www.ncbi.nlm.nih.gov/pubmed/34681179
http://dx.doi.org/10.3390/ph14100955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536968/
https://www.ncbi.nlm.nih.gov/pubmed/34681179
http://dx.doi.org/10.3390/ph14100955

Ejemplares similares